Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niosomal kojic acid + arbutin versus hydroquinone 4% for melasma
IRCT20200623047891N1Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in melasma comparing Niosomal kojic acid + arbutin with Hydroquinone 4% (2 arms). Primary endpoints: Melasma severity, Patient satisfaction and 1 more. Started Jul 2020; status: completed.
02
Drugs
Kojic acidarbutinhydroquinone
03
Conditions
melasma
Beyond the preview
Go deeper on IRCT20200623047891N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200623047891N1.